NASDAQ: NEXI - NexImmune, Inc.

Yield per half year: -99.97%
Dividend yield: 0.00%
Sector: Healthcare

Share chart NexImmune, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About NexImmune, Inc.

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform.

more details
The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. The company was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2021-02-12
ISIN US65344D1090
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.neximmune.com
Цена ао 0.0001
Change price per day: 0% (0.0001)
Change price per week: 0% (0.0001)
Change price per month: 0% (0.0001)
Change price per 3 month: -99.93% (0.14)
Change price per half year: -99.97% (0.33)
Change price per year: -100% (3.15)
Change price per 3 year: -100% (4.12)
Change price per year to date: -99.91% (0.1151)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 0.6519 10
P/E 0 0
EV/EBITDA 0.03 10
Total: 5

Efficiency

Title Value Grade
ROA, % -376.36 0
ROE, % -921.57 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0024 10
Total: 9.6

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 38.08 5
Yield EPS, % -21.5 0
Total: 3.8
More

Institutions Volume Share, %
Slate Path Capital, LP 37000 0.27
Adage Capital Partners GP L.L.C. 32055 0.23
Allen Operations LLC 25437 0.18
EPIQ Capital Group, LLC 15624 0.11
PNC Financial Services Group, Inc. 12640 0.09
First Manhattan Company 5964 0.04
M28 Capital Management LP 5338 0.04
Geode Capital Management, LLC 4326 0.03
Vanguard Group Inc 3893 0.03
Comerica Bank 3257 0.02



Head Job title Payment Year of birth
Mr. John Trainer M.B.A. Consultant 1.33M 1974 (51 year)
Dr. Daniel P. Bednarik Senior Vice President of Molecular Engineering & Protein Design N/A
Dr. Robert Douglas Knight M.D. Chief Medical Officer 454.77k 1951 (74 years)
Mr. Chad Rubin Senior Vice President of Corporate Affairs N/A
Dr. Jack A. Ragheb M.D., Ph.D. Senior Vice President of Translational Science N/A
Mr. Matthew Schiller Head of Business Development N/A
Mr. Craig R. Jalbert CIRA President, Treasurer, CS, Principal Executive Officer, Financial Off, & Principal Accounting Off 1962 (63 years)
Ms. Karen Haslbeck Head of Human Resources

Address: United States, Gaithersburg. MD, 9119 Gaither Road - open in Google maps, open in Yandex maps
Website: https://www.neximmune.com